What type of study is this?

December 4, 2025JAMA Network OpenOpen Access

Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias

View Full Paper

Ask AI

Bookmark

Authors

PKPareeta Kotecha SSSteven M. Smith WDWILLIAM T. DONAHOO

Discussion

Member takes

Implication

Retrospective analysis shows CGM use reduces mortality and hospitalizations in insulin-treated older adults with diabetes and Alzheimer disease, implying potential benefits over SMBG.

Key Points

CGM use significantly reduces risk of mortality in insulin-treated older adults with diabetes and Alzheimer disease, indicating improved long-term outcomes.
Among 2022 insulin-treated older adults, CGM users had a lower risk of all-cause hospitalization with a hazard ratio of 0.86.
Retrospective cohort study utilized Medicare claims data, finding that CGM users experienced better outcomes compared to self-monitoring of blood glucose users.
Results suggest CGM may enable better glycemic control, but further trials are needed to confirm these findings.

Cite This Study

Kotecha et al. (2025) studied this question.

synapsesocial.com/papers/6930e8dbea1aef094cca3cda https://doi.org/10.1001/jamanetworkopen.2025.41939

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows CGM use reduces mortality and hospitalizations in insulin-treated older adults with diabetes and Alzheimer disease, implying potential benefits over SMBG.

Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias

Discussion

Member takes

Implication

Key Points

Cite This Study

Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider